Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | PTGES | O14684 | 4/20 | 0.84 |
| ▸ | CRYAB | P02511 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | FNTA | P49354 | 1/20 | 0.69 |
| ▸ | FNTB | P49356 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.60 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.60 |
| ▸ | PREP | P48147 | 1/20 | 0.59 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.59 |
| ▸ | BACE1 | P56817 | 1/20 | 0.56 |
| ▸ | CRYAA | P02489 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19194140 | 1.00 | MAPT (1.00) | MAPTUSP2ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL17431708 | 1.00 | MAPT (1.00) | MAPTUSP2ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL6130526 | 1.00 | MAPT (1.00) | MAPTUSP2ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL415761 | 1.00 | MAPT (1.00) | MAPTUSP2ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL5666302 | 1.00 | MAPT (1.00) | MAPTUSP2ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL415760 | 1.00 | MAPT (1.00) | MAPTUSP2ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL20990912 | 0.92 | MAPT (0.85) | MAPTUSP2ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL4735043 | 0.92 | MAPT (0.85) | MAPTUSP2ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL21183478 | 0.92 | MAPT (0.85) | MAPTUSP2ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL21149075 | 0.92 | MAPT (0.85) | MAPTUSP2ALDH1A1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180042899-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-20140050694-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-02-20 | — | — | US | disclosed |
| CN-102245179-A | Therapeutic agent for neurological disorders | UNIV SHEFFIELD | 2011-11-16 | — | — | CN | disclosed |
| US-20110251230-A1 | THERAPEUTICS FOR NEUROLOGICAL DISORDERS | UNIVERSITY OF SHEFFIELD (GB) | 2011-10-13 | — | — | US | disclosed |
| EP-2358364-A1 | THERAPEUTICS FOR NEUROLOGICAL DISORDERS | The University Of Sheffield (GB) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010046710-A1 | THERAPEUTICS FOR NEUROLOGICAL DISORDERS | UNIVERSITY OF SHEFFIELD (GB) | 2010-04-29 | — | — | WO | disclosed |
| US-20090269772-A1 | SYSTEMS AND METHODS FOR IDENTIFYING COMBINATIONS OF COMPOUNDS OF THERAPEUTIC INTEREST | THERASIS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251230-A1 | THERAPEUTICS FOR NEUROLOGICAL DISORDERS | KEAP1, SMN1; SMN2, NFE2L2 | MAPT 123/4885USP2 2228/4885ALDH1A1 379/4885 |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | MAPT 357/4885USP2 3201/4885ALDH1A1 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.